The following information may contain forward-looking statements, including forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning Colfax’s plans, objectives, expectations and intentions and other statements that are not historical or current fact. Forward-looking statements are based on Colfax’s current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements. Factors that could cause Colfax’s results to differ materially from current expectations include, but are not limited to risks and uncertainties regarding Colfax and DJO’s respective businesses and the proposed acquisition, and actual results may differ materially. These risks and uncertainties include, but are not limited to, (i) the ability of the parties to successfully complete the proposed acquisition on anticipated terms and timing, including obtaining required regulatory approvals and other conditions to the completion of the acquisition, (ii) access to available financing on a timely basis and reasonable terms, (iii) the effects of the transaction on Colfax and DJO operations, including on the combined company’s future financial condition and performance, operating results, strategy and plans, including anticipated tax treatment, unforeseen liabilities, future capital expenditures, revenues, expenses, earnings, synergies, economic performance, indebtedness, losses, future prospects, business and management strategies for the management, expansion and growth of the new combined company’s operations, and (iv) other factors detailed in Colfax’s and DJO’s respective reports filed with the U.S. Securities and Exchange Commission on Form 10-K and Form 10-Q. In addition, these statements are based on a number of assumptions that are subject to change. This presentation speaks only as of the date hereof. Colfax disclaims any duty to update the information herein.

This presentation shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended or via an exemption from the requirements of the Securities Act.
Compelling Strategic Transaction

**DJO is a global leader uniquely positioned in $21B orthopedic solutions market**
- Industry-defining products and brands
- Beneficial trends – demographics and increased preventive care
- Diverse solutions across products, channels, and geographies

**Evolves Colfax to higher margins, faster growth and lower cyclicality, with upside opportunities**
- Non-cyclical, steady revenue growth – ~4% CAGR over past 5 years
- >55% gross margins and >20% EBITDA margin in 2017 with upside
- Colfax will use CBS to drive further operating improvement and margin expansion and generate sustainable long-term growth
- Significant bolt-on and adjacent acquisition runway over time

**Expect significant value for Colfax shareholders**
- EPS accretion in first year, excluding transaction-related amortization and one-time costs
- 10% ROIC within 5 years
- Strong free cash flow conversion
- Improved portfolio
Consideration

- Colfax to acquire DJO from Blackstone Group for approximately $3.15 billion in cash
- Attractive Adjusted EBITDA multiple of 11.7x\(^1\)
- Funded by cash, debt, and equity
- J.P. Morgan and Credit Suisse providing committed bridge financing

Commitment to Balance Sheet Strength

- Goal to maintain current credit rating
- Committed to reduce leverage to mid-3x’s by end of 2019
- Exploring options to de-leverage, including potential sale of Air & Gas Handling business
- No share repurchases or material acquisitions until de-leveraging targets are met

Timing/Approvals

- Expected close in Q1 2019, subject to regulatory approvals & customary closing conditions

---

\(^{1}\) LTM as of September 30, 2018.
Introducing DJO Global

- A passionate commitment “to get and keep people moving”
- Iconic brands and category defining products
- Attractive financial performance
- Industry leading positions
- Strong demographic and sector drivers
- Talented and experienced leadership team

*MOTION IS MEDICINE*
## DJO’s Attractive Financial Profile

### Steady, Non-Cyclical Growth

<table>
<thead>
<tr>
<th>Year</th>
<th>Revenue (in millions)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013</td>
<td>$1,021</td>
</tr>
<tr>
<td>2014</td>
<td>$1,088</td>
</tr>
<tr>
<td>2015</td>
<td>$1,114</td>
</tr>
<tr>
<td>2016</td>
<td>$1,155</td>
</tr>
<tr>
<td>2017</td>
<td>$1,186</td>
</tr>
<tr>
<td>TTM</td>
<td>$1,203</td>
</tr>
</tbody>
</table>

Revenue has increased at an average rate of 4% CAGR.

### Exposure to Global Markets

- **U.S.:** 73%
- **Europe:** 20%
- **ROW:** 7%

### Transformation Driving Margin Expansion

<table>
<thead>
<tr>
<th>Year</th>
<th>Adjusted EBITDA (in millions)</th>
<th>Adjusted EBITDA Margin</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013</td>
<td>$201</td>
<td>19.7%</td>
</tr>
<tr>
<td>2014</td>
<td>$217</td>
<td>20.0%</td>
</tr>
<tr>
<td>2015</td>
<td>$221</td>
<td>19.8%</td>
</tr>
<tr>
<td>2016</td>
<td>$221</td>
<td>19.2%</td>
</tr>
<tr>
<td>2017</td>
<td>$257</td>
<td>21.7%</td>
</tr>
<tr>
<td>TTM</td>
<td>$269</td>
<td>22.3%</td>
</tr>
</tbody>
</table>

### Serving Large & Growing Healthcare Segments

- **Reconstructive:** 26%
- **Prevention & Rehabilitation:** 74%

---

Source: DJO Finance LLC, financial statements; Colfax adjustments

(1) TTM as of September 2018.

(2) See appendix for reconciliation of non-GAAP financial measures.
## Iconic Brands and Industry Defining Products

<table>
<thead>
<tr>
<th><strong>Custom Knee Braces</strong></th>
<th><strong>Removable Braces</strong></th>
<th><strong>Surgical Implants</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>From elite athletes to weekend warriors, more than 20 years of industry leading protection</td>
<td>Pioneer in the space with #1 global market share</td>
<td>Leader in differentiated technology and upper extremity solutions</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Electrotherapy &amp; Rehabilitation Equipment</strong></th>
<th><strong>Muscle Growth and Recovery Stimulation</strong></th>
<th><strong>Connected Brace Technology</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Broad portfolio for physical therapists and athletic trainers</td>
<td>Used by pro athletes globally</td>
<td>Cloud-based remote monitoring</td>
</tr>
</tbody>
</table>
## DJO’s Market Leading Positions

### Prevention & Rehabilitation – ($4 billion market)

**BRACING:** Leader with comprehensive offering of rigid and soft bracing for use in both functional and acute settings

**REHABILITATION:** Musculoskeletal, neurological and soft tissue treatment products including electrotherapy, continuous passive motion (CPM) devices, traction devices, heat and cold therapy and treatment tables

**FOOTCARE:** Diabetic footwear, custom orthotics and compression hosiery with sales into consumer, podiatry, and retail channels

### Reconstructive – ($17 billion market)

**SURGICAL IMPLANTS:** One of the fastest-growing adult reconstructive surgery businesses; launched new reverse shoulder in U.S. which is now the leading product worldwide in its class

**BONE GROWTH STIMULATION:** Technology leader in bone growth stimulation market with products for spine fusions and fractures; powered by a proprietary continuous magnetic field (“CMF”) technology

Source: DJO Global internal data.
PERFORMANCE
- Athletic braces
- Muscle stimulation

PREVENTION
- Pre-op braces
- Slings
- Protective solutions
- Orthotic shoes

SURGICAL
- Shoulders
- Knees
- Hips
- Bone growth stimulators

RECOVERY
- Post-op braces
- Bone growth stimulators
- DVT
- Cold therapy

REHAB
- Traction devices
- Electrotherapy
- Heat/cold therapy

Software billing solution for providers

Connected medicine
Macro Trends Support Sustained Growth

Population Trends

AGING POPULATION: Rise of diseases and injuries that require surgeries or other orthopedic treatment

RISING OBESITY: Increased likelihood of orthopedic injury and need for orthopedic products

REDUCTION IN OPIOID USAGE: Shift to utilizing non-opioid pain relief solutions, including bracing

Healthcare Trends

INCREASED GLOBAL ACCESS TO HEALTHCARE: Higher levels of healthcare coverage with access to orthopedic care

MORE BUNDLED CARE REIMBURSEMENT: Shift to bundled payments that focus on outcomes and incentivize bracing spend

SHIFT TO OUTPATIENT CARE IN U.S.: Shift of surgical procedures out of hospitals is increasing need for post-operative rehabilitation

CONNECTED MEDICINE: Rising use of remote patient monitoring to increase patient treatment compliance

Sources: Global Data; Leading Consulting Firm Analysis

Orthopedic Patient Volume Growth
(Patients in U.S. and Europe; in millions)

Hip and Knee Moving to Outpatient


9.5 10.4 11.5 12.8 14.3 15.7 17.2

4.5% CAGR

2016 2026

85% 49%

15% 51%
Industry Leading Innovation

**AltıVate Reverse Shoulder**
- #1 reverse shoulder globally
- Shoulder revenue increased 20% CAGR (2015-2018)
- Reverse shoulder now >50% of all shoulder replacement procedures and growing
- Leadership and differentiation driving share gain

**X4 Smart Brace**
- Pioneering internet-connected smart brace
- Cloud-based connectivity throughout continuum of care
- Promotes patient progression, compliance & engagement
- Robust pipeline of connected product launches

**MotionMD**
- Cutting-edge SaaS platform
- Most widely used digital billing tool – serving nearly 20% of U.S. orthopedic clinics
- Decision support and workflow benefits

Source: Internal DJO Global data.
DJO Consistent with Disciplined M&A Approach

**Acquire Good Companies**
- Attractive markets
- Strong brands and solutions
- Opportunities to improve and expand

**Focus and Empower Top Talent**
- Independent businesses
- Great leaders, strong teams, winning spirit
- Lean, high value corporate

**Use CBS to Make Them Great**
- Values
- Tools & processes
- Way of working
Colfax/DJO Value Creation Opportunity

- Finish transformation, embrace CBS culture
- Fuel strong innovation-driven implants growth
- Re-invigorate vitality in Prevention & Rehabilitation
- Leverage clinic workflow position
- Accelerate/expand via acquisitions

### DJO Performance Goals

- **Ramp to 4-5% annual growth**
- **Improve EBITDA margins >50 bps per year**
- **Increase unlevered FCF to $200+ million p.a. by year 3**
- **Achieve Colfax 10% ROIC target by year 5**
## DJO Meets Colfax Acquisition Criteria

### Colfax New Platform Criteria

<table>
<thead>
<tr>
<th>Colfax New Platform Criteria</th>
<th>DJO a Clear Fit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Attractive end-markets</td>
<td>✓ Steady growth and beneficial secular trends</td>
</tr>
<tr>
<td>Market leadership</td>
<td>✓ Low cyclicality and volatility</td>
</tr>
<tr>
<td>Improve margin structure</td>
<td>✓ #1 in Bracing and Rehab</td>
</tr>
<tr>
<td>Improve margin structure</td>
<td>✓ Leading positions across the continuum of orthopedic care</td>
</tr>
<tr>
<td>Acquisition and innovation headroom</td>
<td>✓ &gt;55% gross margins</td>
</tr>
<tr>
<td></td>
<td>✓ &gt;20% EBITDA margins</td>
</tr>
<tr>
<td></td>
<td>✓ New product launches and expanded technology-driven healthcare product line</td>
</tr>
</tbody>
</table>
### Successfully Reshaping Colfax

<table>
<thead>
<tr>
<th>Year</th>
<th>Fluid Handling</th>
<th>Air &amp; Gas Handling</th>
<th>Fabrication Tech.</th>
<th>Medical Technology</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015</td>
<td>Operational improvement</td>
<td>Pivot to industrial markets</td>
<td>Foundation</td>
<td>Build-out platform</td>
</tr>
<tr>
<td>2016</td>
<td>DIVEST</td>
<td>Structural shift to margin/growth</td>
<td>Technology development &amp; investment</td>
<td></td>
</tr>
<tr>
<td>2017</td>
<td>Siemens Turbo</td>
<td>AMI, TBI, HKS, Sandvik</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2018</td>
<td>EXPLORE STRATEGIC OPTIONS</td>
<td>Sandvik, Siemens Turbo</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2019</td>
<td>GCE</td>
<td>GCE</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Faster, less cyclical growth
- Structurally higher margin potential
- Innovation upside
- More attractive capital deployment landscape
Financing and Balance Sheet Overview

**Financing Structure**
- Approximately $3.15 billion total consideration to be financed with:
  - $100 million of cash on hand
  - $2.4-$2.7 billion of debt: combination of term loans and senior bonds
  - $500-$700 million of equity or equity-linked securities
- J.P. Morgan and Credit Suisse providing committed bridge financing
- DJO outstanding debt to be extinguished at close

**Balance Sheet**
- Pro forma leverage expected to be 4.7x-4.9x at closing
- Committed to reduce leverage to mid-3x’s by end of calendar 2019
- Expected liquidity of >$700 million post-closing will allow Colfax to maintain balance sheet strength and flexibility
- Expect to maintain current credit ratings
Capital Allocation Priorities

Near-Term Focus

- Committed to reduce debt leverage to mid-3x’s in 2019
- Will evaluate de-leveraging options to repay debt, including the potential sale of Air and Gas Handling
- No material acquisitions or share repurchases until leverage target met

Long-Term Financial Policy

- Manage leverage to pre-acquisition levels
- Continue to shape portfolio to create value & minimize volatility
- Long-term goal to achieve investment grade ratings
Compelling Strategic Transaction

- Diversifying portfolio with global leader in orthopedic care, uniquely positioned to benefit from demographic and industry trends

- Executing on our strategy to make portfolio higher margin, faster growth, and less cyclical

- Expecting significant long-term value creation from increasing top-line growth, enhancing margins and driving cash flow
Colfax has provided in this presentation financial information that has not been prepared in accordance with GAAP, including Adjusted EBITDA for DJO Global. DJO Global provided Colfax with this information, which was derived from DJO Global’s historical unaudited financial statements for the twelve months ended September 29, 2018 and has not been audited or reviewed by Colfax’s or DJO Global’s independent public accountants. DJO Global defines Adjusted EBITDA as net income (loss) attributable to DJO Global plus interest expense, net, income tax provision (benefit), and depreciation and amortization, further adjusted for certain non-cash items, non-recurring items and other adjustment items as permitted in calculating covenant compliance and other ratios under the agreements governing the outstanding debt of DJO Global’s subsidiary DJO Finance, LLC (DJO Finance). Adjusted EBITDA should not be considered as an alternative to net income (loss) attributable to DJO Global or other performance measures presented in accordance with GAAP, or as an alternative to cash flow from operations as a measure of liquidity.

Colfax believes this presentation of DJO Global’s Adjusted EBITDA is useful and helps management, investors and rating agencies enhance their understanding of the impact of the DJO Global acquisition on Colfax’s financial performance. However, Adjusted EBITDA does not have a standardized meaning, and different companies may use different Adjusted EBITDA definitions. Therefore, DJO Global’s definition of Adjusted EBITDA may not be comparable to the definitions used by other companies.

Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information calculated in accordance with GAAP. Investors are encouraged to review the reconciliation of Adjusted EBITDA to the most directly comparable GAAP financial measure. A reconciliation of Adjusted EBITDA to GAAP net income has been provided in the Appendix.
## Non-GAAP Reconciliation
(unaudited)

<table>
<thead>
<tr>
<th></th>
<th>2013</th>
<th>2014</th>
<th>2015</th>
<th>2016</th>
<th>2017</th>
<th>TTM September 29, 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Adjusted EBITDA</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net income attributable to DJO Global</td>
<td>$(203,434)</td>
<td>$(90,534)</td>
<td>$(340,927)</td>
<td>$(286,303)</td>
<td>$(35,894)</td>
<td>$397</td>
</tr>
<tr>
<td>Discontinued operations</td>
<td>13,101</td>
<td>(21,742)</td>
<td>157,580</td>
<td>(1,138)</td>
<td>(309)</td>
<td>(567)</td>
</tr>
<tr>
<td>Interest expense, net</td>
<td>177,542</td>
<td>174,325</td>
<td>172,290</td>
<td>170,082</td>
<td>174,238</td>
<td>181,091</td>
</tr>
<tr>
<td>Income tax provision (benefit)</td>
<td>17,451</td>
<td>(4,720)</td>
<td>12,256</td>
<td>(6,853)</td>
<td>(60,720)</td>
<td>(55,196)</td>
</tr>
<tr>
<td>Depreciation and amortization</td>
<td>118,919</td>
<td>119,157</td>
<td>117,455</td>
<td>117,893</td>
<td>111,261</td>
<td>107,646</td>
</tr>
<tr>
<td>Impairment of goodwill</td>
<td>49,600</td>
<td>-</td>
<td>-</td>
<td>160,000</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Inventory adjustments</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>18,013</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Loss on disposal of assets, net</td>
<td>536</td>
<td>(761)</td>
<td>777</td>
<td>949</td>
<td>1,403</td>
<td>295</td>
</tr>
<tr>
<td>Restructuring and reorganization (1)</td>
<td>11,815</td>
<td>28,363</td>
<td>12,843</td>
<td>16,838</td>
<td>58,775</td>
<td>41,121</td>
</tr>
<tr>
<td>Acquisition integration</td>
<td>1,863</td>
<td>331</td>
<td>8,635</td>
<td>10,350</td>
<td>2,106</td>
<td>2,096</td>
</tr>
<tr>
<td>Blackstone monitoring fee</td>
<td>7,000</td>
<td>7,000</td>
<td>7,000</td>
<td>7,000</td>
<td>6,225</td>
<td>975</td>
</tr>
<tr>
<td>Loss on modification and extinguishment of debt</td>
<td>1,059</td>
<td>938</td>
<td>68,473</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Financial reporting alignment</td>
<td>5,655</td>
<td>4,844</td>
<td>4,455</td>
<td>14,374</td>
<td>(156)</td>
<td>(9,071)</td>
</tr>
<tr>
<td><strong>Adjusted EBITDA</strong></td>
<td>$201,107</td>
<td>$217,201</td>
<td>$220,837</td>
<td>$221,205</td>
<td>$256,929</td>
<td>$268,787</td>
</tr>
<tr>
<td>Future cost savings</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>9,050</td>
<td>9,620</td>
<td>25,538</td>
</tr>
<tr>
<td>Stock compensation expense</td>
<td>2,155</td>
<td>1,869</td>
<td>1,805</td>
<td>3,188</td>
<td>3,695</td>
<td>4,522</td>
</tr>
<tr>
<td><strong>Leverageable Adjusted EBITDA</strong></td>
<td>$203,262</td>
<td>$219,070</td>
<td>$231,692</td>
<td>$234,013</td>
<td>$286,162</td>
<td>$293,842</td>
</tr>
</tbody>
</table>

(1) Consists of costs related to the company’s business transformation projects to improve the company’s operational profitability and liquidity.